Current Updates on Microbiota Restoration and Modulation by Functional Products

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Microbiology".

Deadline for manuscript submissions: closed (30 December 2023) | Viewed by 1720

Special Issue Editor

Special Issue Information

Dear Colleagues,

The human gut microbiota is vital in maintaining host health and well-being. Recent research has highlighted the significant impact of dysbiosis, characterized by alterations in the composition and function of the gut microbiota, on various diseases and disorders. Microbiota restoration and modulation through functional products have emerged as promising strategies to promote healthy gut microbiota and prevent or treat associated conditions. This Special Issue aims to provide a comprehensive overview of microbiota restoration and modulation advancements using functional products. It explores the latest research findings, methodologies, and technologies used to understand the complex interactions between gut microbiota and functional products. Furthermore, it delves into the diverse range of functional products, including prebiotics, probiotics, synbiotics, postbiotics, and dietary interventions, that have shown potential in modulating the gut microbiota and improving human health.

The Special Issue encompasses a broad spectrum of research, covering both in vitro and in vivo studies, clinical trials, and translational research. Contributions include investigations into the mechanisms of action through which functional products interact with the gut microbiota, the effects of these interactions on host health, and the optimization of functional product formulations for enhanced microbiota modulation.

Topics covered in this Special Issue include, but are not limited to:

- Elucidation of the mechanisms of action of functional products on the gut microbiota composition and activity;
- Characterization of the impact of functional products on host metabolism, immune response, and overall health;
- Clinical trials evaluating the efficacy and safety of functional products for microbiota modulation;
- Optimization of functional product formulations, including encapsulation techniques, to enhance their stability and delivery to the gut;
- Novel approaches and technologies for targeted delivery of functional products to specific gut regions;
- Investigations into the potential of novel functional products, such as microbial-derived therapeutics and genetically engineered probiotics, for microbiota restoration and modulation;
- Application of functional products for preventing and treating specific diseases associated with dysbiosis, including metabolic disorders, gastrointestinal disorders, and immune-related conditions.

Dr. Emanuel Vamanu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • probiotic
  • prebiotic
  • microbiota
  • functional products
  • extraction
  • fermentation
  • bee products
  • pattern
  • degenerative diseases
  • oxidative stress
  • vegan food
  • probiotic beverages
  • kombucha
  • in vitro study

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 576 KiB  
Article
In Vitro and In Vivo Antihyperglycemic Effects of New Metabiotics from Boletus edulis
by Anca Zanfirescu, Ionela Avram, Florentina Gatea, Răzvan Roșca and Emanuel Vamanu
Life 2024, 14(1), 68; https://doi.org/10.3390/life14010068 - 30 Dec 2023
Viewed by 1133
Abstract
The increasing incidence of diabetes has prompted the need for new treatment strategies, including natural products that reduce glycemia values. This work examined the in vitro and in vivo antihyperglycemic effects of new metabiotics derived from Boletus edulis extracts. The metabiotics were obtained [...] Read more.
The increasing incidence of diabetes has prompted the need for new treatment strategies, including natural products that reduce glycemia values. This work examined the in vitro and in vivo antihyperglycemic effects of new metabiotics derived from Boletus edulis extracts. The metabiotics were obtained from 100% B. edulis, and two other products, CARDIO and GLYCEMIC, from Anoom Laboratories SRL, which contain other microbial species related to B. edulis. Our in vitro investigations (simulations of the microbiota of patients with type 2 diabetes (T2D)) demonstrated that B. edulis extracts modulate the microbiota, normalizing its pattern. The effects were further tested in vivo, employing a mouse model of T2D. The tested extracts decreased glycemia values compared to the control and modulated the microbiota. The metabiotics had positive effects on T2D in vitro and in vivo, suggesting their potential to alleviate diabetes-associated microbiota dysbiosis. Full article
Show Figures

Figure 1

Back to TopTop